Latest News by Industry
CHICAGO--(BUSINESS WIRE)--Nov 27, 2022--
Ahead of its planned spinoff from GE the first week of January 2023, GE Healthcare reveals over 40 solutions that aim to improve patient outcomes and increase healthcare efficiency at the Radiological Society of North America’s (RSNA) 2022 Annual Meeting.
Drawing on more than 100 years of history as a trusted medical technology innovator 1, GE Healthcare is closely connected with healthcare systems globally. Knowing the industry is under immense pressure, the company is proud to introduce its latest innovations to help solve for the biggest challenges in healthcare today – including rising cost pressures, increasing staff shortages, mounting expectations to deliver outcomes, and more – while also aiming to improve healthcare in the future.
“ With an unparalleled combination of technology solutions and clinical understanding, we have a unique ability to help solve industry challenges by delivering clinical and operational insights through integrated data, analytics and devices,” said Peter Arduini, CEO of GE HealthCare. “A new era is coming for GE Healthcare and with it, we hope to help healthcare transform as a whole by advancing precision diagnostics, improving capacity and efficiency, and increasing patient access.”
Connecting healthcare for better patient outcomes
GE Healthcare aims to erase segmented care and fill in the gaps in healthcare systems’ workflows to increase access and improve outcomes for patients across the care continuum - all while achieving greater connectivity, resilience, and agility to enhance the clinician experience.
GE Healthcare delivers connected care across care pathways with leading imaging, digital and patient monitoring capabilities that help improve patient care throughout each individual’s journey.
To help clinicians deliver care that’s more personal and precise, while also enabling greater healthcare system efficiencies, GE Healthcare offers several game-changing solutions:
Strategic collaborations in precision oncology
As an open-architecture, multi-dimensional ecosystem, GE Healthcare helps connect teams, multimodal data, and decisions at every step – from discovery to diagnosis to treatment and monitoring – with intelligently efficient innovations designed to help clinicians deliver precise, personalized care.
In concert with collaborators in adjacent fields who are well-versed in their disciplines, GE Healthcare is proud to work together with some of healthcare’s leading innovators across care pathways, including oncology.
Some of GE Healthcare’s recent collaborations in cancer care include:
Ushering in a new era of healthcare with innovative diagnostics
Looking towards the future, GE Healthcare is uniquely positioned to advance precision care through theranostics.
Where most medical therapies are designed with the ‘average’ patient in mind, theranostics brings together diagnostics and therapeutics to provide a more targeted and personalized treatment than ever before 5. Clinicians and patients are especially seeing success with theranostics in prostate cancer – a highly manageable disease, but one that is difficult to treat when diagnosed at a late stage, claiming more than 1.4 million lives annually 6 .
To advance this growing field and help clinicians improve patient outcomes, GE Healthcare is proud to be the only partner with solutions covering the breadth of steps required from discovery to diagnosis to treatment.
“As the only partner with solutions spanning from pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, SPECT/CT, and advanced oncology and digital solutions, we cover the breadth of steps from discovery to diagnosis to treatment,” said Jamie McCoy, General Manager, Theranostics and Radiotherapeutics, GE Healthcare. “Ultimately, we hope that by advancing the integration of diagnostics and therapeutics, we can help usher in a new era in healthcare that enables clinicians to provide more targeted and personalized therapies for improved patient outcomes than ever before.”
This includes several standout products to enable greater adoption of theranostics in practice:
For more information on GE Healthcare and its innovative solutions at RSNA, visit Booth 7324 or the RSNA 2022 events page.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
_______________
1https://www.gehealthcare.com/about/about-ge-healthcare-systems#what-we-do
2 GE Healthcare data on file.
3 Scalability and upgradability are subject to the availability and compatibility of new capabilities and products.
4 0.23sec and 19.5msec are 510k pending and not available for sales in all countries. 19.5msec effective temporal resolution is achieved by a 6x improvement of motion-blur reduction while maintaining high spatial resolution as demonstrated in cardiac phantom testing. The reduction in motion artifacts is comparable to a 0.039 equivalent gantry rotation speed with effective temporal resolution of 19.5 msec, as demonstrated in mechanical and mathematical phantom testing.
5 Pharmacy Management System Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027). Mordor Intelligence. Accessed November 17, 2022. https://www.mordorintelligence.com/industry-reports/pharmacy-management-system-market#:~:text=Where%20most%20medical%20therapies%20are,personalized%20therapy%20than%20ever%20before
6 “Cancer.” World Health Organization. Feb 3, 2022. Accessed Jun 1, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
7 Svedjehed et al. “Demystifying solid targets: Simple and rapid distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11.” Nuclear Medicine and Biology. Volumes 104–105, January–February 2022, Pages 1-10. https://doi.org/10.1016/j.nucmedbio.2021.10.002
8 CE marked. 510(k) pending in the U.S. Not for sale in the U.S. Not cleared or approved by the U.S. FDA.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221127005061/en/
CONTACT: Kyerstin Hill
External Affairs, GE Healthcare
Kyerstin.hill@ge.com
708-738-7741
KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RADIOLOGY HEALTH ONCOLOGY MEDICAL DEVICES
SOURCE: GE Healthcare
Copyright Business Wire 2022.
PUB: 11/27/2022 09:00 AM/DISC: 11/27/2022 09:02 AM
http://www.businesswire.com/news/home/20221127005061/en